If a patient receives a continuous glucose monitor device through their medical benefit, they may be more adherent and may ...

Continuous glucose monitoring, compared with fingerstick tests, was feasible and accurate in an inpatient setting among patients and nurses.

The implementation of an inpatient continuous glucose monitoring policy was accurate ... The researchers also administered a System Usability Scale questionnaire to nurses who engaged with the ...

Leveraging rapid technological advances for human health is a global trend, driving the rise of biomedical engineering ...

Biosensors that measure glucose are now available without a prescription. Wearing one burst my wellness bubble in ways I wasn ...

SENS' latest regulatory clearance is likely to simplify diabetes management with the help of a long-lasting CGM system.

Remote patient monitoring has exploded since the pandemic. In just four years from the beginning of 2019 through 2022, ...

DexCom ( DXCM -1.08%) is not a stock that investors should be rushing to sell. It has a few different opportunities to ...

With the company's market cap of $28 billion today, it's important to recognize that DexCom (NASDAQ: DXCM) is already one of ...

The FDA cleared Eversense 365 as the first 1-year integrated continuous glucose monitoring (CGM) system for adults with type ...

Little did I realize a few grapes could send my blood sugar soaring until I tried the first glucose monitor without a ...